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The aim of this study was to compare the efficacy of 100 pg of salbutamol inhaled from a new metered-dose powder 
inhaler (MDPI, Leiras Taifun@, Finland) with that of a same dose of salbutamol inhaled from a conventional 
pressurized metered-dose inhaler with a large volume spacer (pMDI+S) in protecting against methacholine (Mch) 
induced bronchoconstriction. 
This was a 3 day, randomized, cross-over, partly blinded, placebo-controlled multicentre study where the 
pMDI+S was used as an open control. Twenty-six asthmatic outpatients with a baseline FEV, 260% of predicted 
and with bronchial hyperreactivity (PD,, FEV, I 890 ,ug of Mch) were studied. On each study day the patients 
underwent an Mch provocation 30 min after inhaling placebo from the MDPI or a dose of 100 lug of salbutamol 
from the MDPI and from the pMDI+S. PD,, FEV, and dose-response slope [DRS; maximal change in FEV, 
(%)/dose of Mch +mol)] were used to evaluate efficacy. 
The median values of PD,, FEV, were 250, 622 and 1737 ,ug after placebo MDPI, salbutamol pMDI+S and 
salbutamol MDPI, respectively. The corresponding DRS values were - 1 l.O%, - 4.5% and - 2.0% pmol ~ ‘. With 
both parameters, all differences were statistically significant (NO.05). 
In conclusion, 1OOpg of salbutamol inhaled from Leiras Taifun @ MDPI offers better protection against 
Mch-induced bronchoconstriction than 100 pug of salbutamol from a pMD1 connected to a large volume spacer 
device. 
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Introduction 
Inhalation therapy of asthma is still most commonly carried 
out with pressurized metered-dose inhalers (pMDIs), which 
were invented over 40 yr ago, and have remained virtually 
unchanged since then. However, several factors have 
recently contributed to the development of alternative 
inhalation devices: for environmental reasons the use of 
chlorinated aerosol propellants (CFCs) should be reduced 
(1); also, CFCs may irritate mucous membranes of the 
human bronchi, and cause bronchoconstriction (1,2); in 
addition, there exist several practical difficulties in the use 
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of pMDIs, of which the most frequent problem is the 
inability of some patients to coordinate the actuation of 
aerosol with inhalation (3). The use of spacer devices 
together with pMDIs diminished the co-ordination prob- 
lems. However, most of them are large and cumbersome 
devices inconvenient to handle and carry, which impairs 
patient compliance. Therefore, dry powder systems have 
become a remarkable alternative in the inhalation therapy 
of asthma (4). 
Recently, Leiras Oy, Finland, has developed a novel 
breath-actuated metered-dose powder inhaler (MDPI), 
Taifun@ (Plate l), which contains 200 doses of salbutamol 
(100 pg per dose). It allows the inhalation of the medication 
without employing propellants and overcomes the hand- 
lung coordination problem. In addition, Taifuna provides 
a high respirable fraction and is highly efficient in delivering 
the salbutamol dose into the lungs (5). The aim of this study 
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PLATE 1. The studied MDPI. 
was to compare the ability of a 1OOpg dose of salbutamol 
to protect against methacholine (Mch) induced broncho- 
constriction when inhaled either from the Leiras Taifun’= 
MDPI or from a conventional pMD1 connected to a large 
volume spacer device (S). 
Methods 
DESIGN 
This was a randomized, partly double-blinded, placebo- 
controlled, cross-over study, which was carried out simul- 
taneously in four centres in Finland. Each subject attended 
the laboratory three times after the screening visit. The 
sessions were at least 24 h apart, and the subjects completed 
the study within 2 weeks from the screening visit. 
SUBJECTS 
Twenty-six outpatients (20 female, six male) having a 
chronic asthma aged 19-64 years, with a forced expiratory 
volume in 1 s (FEV,) of at least 60% of predicted (6), and a 
provocative dose of Mch which causes 20% decline in 
patient’s FEV, value (PD,, FEV,) of 89Opg or less, were 
recruited from the outpatients of four clinics of pulmonary 
diseases. The patients fulfilled the ATS criteria for asthma 
determined by the attending chest physician. The demo- 
graphic characteristics of the enrolled patients are listed in 
Table 1. All patients were of Caucasian origin. Eight of 
them were ex-smokers, and the others had never smoked. 
Only one patient had no prior medication for asthma. 
Twenty-three patients used short-acting, and three of them 
also long-acting, inhaled &-adrenoceptor agonist drugs. 
Fourteen of the patients used inhaled and one oral steroids, 
and three used inhaled non-steroidal anti-inflammatory 
medication. One used inhaled anticholinergics, another a 
combination product of an inhaled anticholinergic and 
&adrenoceptor agonist and two patients used nasal ster- 
oids. Additionally, 14 patients had a regular medication for 
other than respiratory or allergic conditions. 
The patients were instructed to avoid heavy meals and 
caffeinated beverages on the morning of the study days. 
Further, the use of inhaled and oral short-acting &-agonists 
was prohibited for 12 h, inhaled long-acting &-agonists for 
48 h, inhaled anticholinergics for 24 h and theophylline and 
its derivatives for 72 h prior to each study visit (7). 
Additionally, the patients should not have used hydroxy- 
zine and cetirizine for 5 days, ebastine for 7 days, astemizole 
for 3 months and all other antihistamines for 72 h prior 
to the study. Concomitant medication with inhaled or oral 
glucocorticosteroids and inhaled nedocromil or sodium 
cromoglycate, with a constant dosage at least 1 month prior 
to and during the study, was allowed. All subjects gave a 
written informed consent, and the study was approved by 
the ethics committees of each hospital. 
INSTRUMENTS AND DRUGS 
Pulmonary function was measured with Vitalograph Com- 
pact Spirometers’K\ (Vitalograph Ltd Buckingham, U.K) 
calibrated by the supplier prior to the study. The calibration 
was checked daily during the study. Mch was delivered 
with an automatic, inhalation-synchronized, dosimeter jet 
nebulizer (Spira Elektro 2, Respiratory Care Centre, 
Hlmeenlinna, Finland), which was adjusted to nebulize for 
0.5 s after an inhalatory threshold volume of 100 ml. With 
these settings the mean * SD output of the dosimeter is 
7.1 f 0.5~1 per inhalation (8). Mch chloride (Leiras Oy, 
Turku, Finland) was diluted with physiological saline to 
provide concentrations of 2.5 and 25 mg ml ~ i (8). 
Placebo (lactose particles only) or 100,ug of salbutamol 
was administered from the Leiras MDPI in a double-blind 
manner. A dose of 1OOpg of salbutamol was administered 
from Ventoline* pMD1 connected to a Volumati@ spacer 
(Glaxo Wellcome Ltd, U.K.) which served as an open 
control. In order to optimize the function of the devices, an 
inhalation technique recommended by the manufacturers 
was followed. When using the MDPI the patients after 
having loaded the device exhaled normally to functional 
residual capacity (FRC) and then took a normal, slow tidal 
volume inhalation through the device. When the pMDI+ S 
was used, after shaking the canister the patients exhaled to 
FRC, placed the mouthpiece firmly between their lips and 
then, after a wait of 24 s, took a slow and deep inhalation. 
Both procedures was followed by a period of 10 s breath 
holding. 
STUDY PROCEDURE 
On each visit pulmonary function of the patients was 
established by having them do repeated spirometric 
measurements at 1 min intervals, until three FEV, values 
were obtained from three valid spirometric efforts with at 
least two values within a 100 ml range. The higher one of 
these two values was recorded. This procedure was repeated 
3 min after inhalation of 36pg of saline, and this post-saline 
FEV, was considered as the baseline value. The pulmonary 
function measurements were performed always at the 
same time between 7 a.m. and 11 a.m., and less than 
30 min before inhalation of the study drug. The base- 
line FEV, was required to be 260% of predicted, and 
580 O.-P. SEPPiiLA E7 AL. 
TABLE 1. Summary of demographic characteristics of the 
recruited patients (n=26) 
Characteristic Mean f SD Range 
Age (years) 43.5 * 13.9 19-64 
Weight (kg) 77.3 =k 16.0 55-I 12 
Height (cm) 167&t 1533187 
FEV, (1) 2.68 f 0.62 1.834.23 
FEV, (%) 79.9 It 11.2 60-100 
PD,, FEV, @g), median 219 44880 
DRS (% pmol - ‘), median - 12.1 - 64.8 to - 3.6 
TABLE 2. The variability of FEV, (%) on each medication 
day when compared with other study visits, presented as 
mean f SD (range) 
Study day Study visit Variability (%) 
Day 1 Screening visit 0.5 f 4.3 ( - 9.0-10.0) 
Day 2 Screening visit - 0.3 zk 4.9 ( - 9.0-8.0) 
Day 1 - 0.4 f 5.2 ( - 9.0-12.0) 
Day 3 Screening visit 1.3 f 4.2 ( - 6.0-12.0) 
Day 1 1.0 f 4.5 ( - 5.0-12.6) 
Day 2 1.5 * 4.5 ( - 6.0-12.0) 
290% of the pre-saline value before the patient could 
proceed to the inhalation of the study drugs and the 
Mch provocation. 
After the baseline level of pulmonary function had been 
established, the study drugs were inhaled. The Mch provo- 
cation was initiated 30 min after this. It was conducted 
according to the tidal breathing method described by 
Nieminen et al, (8). The tidal breathing was controlled with 
a flow indicator so that the inspiratory flow rate reached 
but did not exceed 0.51~~‘. Mch doses (18, 36, 71, 110, 
180, 360, 530, 890, 1600 and 23OOpg) were administered in 
a cumulative fashion at 5 min intervals. FEV, was 
measured twice, 3 and 4 min after each Mch dose, and the 
higher value of these two was recorded. The Mch provoca- 
tion was terminated when FEV, fell at least 20% or when 
the maximal Mch dose was reached. The decline in FEV, 
was plotted against the Mch dose on a logarithmic scale, 
and the provocative dose causing a 20% decline in FEV, 
(PD,, FEV,) was calculated. Since it was possible that a 
measurable PD,, FEV, value could not be obtained in 
some of the patients after active medication another 
measure of airway reactivity, the dose-response slope 
(DRS) (9) was calculated. The DRS is obtained by dividing 
the achieved percentage change in FEV, by the cumulative 
dose @mol) of Mch used. It can be determined for all 
patients and in all conditions, even if the decline in FEV, is 
less than the 20% required for PD,, FEV,. 
After the study procedures the bronchoconstriction 
caused by Mch was reversed with a dose of 200,ug of 
salbutamol from a pMDI+S, and 15 min later FEV, was 
recorded again. The patients were allowed to leave the 
study premises only after their FEV, was at least 90% of the 
baseline level. As a safety precaution the patients’ electro- 
cardiogram (ECG), blood pressure (BP) and heart rate 
(HR) were recorded on each visit before and after the study 
procedures. In addition, all adverse events (AEs) during the 
study were recorded. 
DATA ANALYSIS 
As PD,, FEV, data could not be obtained for all the 
subjects, the unestimable values were replaced with an 
arbitrary value of 2500, which exceeds the highest used 
cumulative Mch dose of 23OOpg. Thus, non-parametric 
statistics had to be used. The results are presented as 
medians and ranges, unless otherwise indicated. Non- 
parametric Friedman’s analysis of variance (ANOVA) with 
pairwise comparisons was used in the analysis of 
PD,,FEV, and DRS. In addition, for these two variables, a 
difference between the treatments for each patient was 
obtained, and a 90% confidence interval (CI) for the median 
of these differences was calculated (lO).A P value of 0.05 or 
less was considered statistically significant. The statistical 
analyses were performed with the SA@ System software 
package. 
Results 
All the recruited 26 patients completed the study according 
to protocol. The mean f standard deviation (SD) of the 
baseline pulmonary function characteristics are presented 
in Table 1. The variability of the baseline FEV, between the 
four study visits ranged from - 9.0% to + 12.6% (Table 2), 
and the saline inhalation did not have any effect on the 
FEV, level. 
After treatment with placebo MDPI, a PD,, FEV, value 
could be determined for all the patients, whereas, this could 
not be done for 12 and six patients after treatment with 
1OOpg of salbutamol from the Leiras MDPI and the 
pMDI+ S, respectively. 
The effects of the study medication on PD,, FEV, and 
DRS levels are summarized in Table 3 and Fig. 1. Analysed 
by either parameter, the rank order of bronchoprotective 
efficacy for the treatments was placebo MDPI <salbutamol 
pMDI+S <salbutamol MDPI. Friedman ANOVA with 
pairwise comparisons resulted in statistically significant 
(PcO.05) differences between all the treatments. For 
PD,, FEV,, the medians and 90% CIs of the individual 
differences between the treatments are presented in Table 4. 
The medians (90% CI) of the differences between treatments 
were as follows: between salbutamol and placebo MDPI 
10.2%prnol- ’ (5.5-13.7%pmol- ‘), between salbutamol 
MDPI and pMDI+S 2.3%pmol- ’ (0.8-5.1%pmol- ‘) 
and between salbutamol pMDI+S and placebo MDPI 
5.1%pmol-’ (3.0-12.9%pmol-‘). 
There were neither statistically nor clinically significant 
changes in the BP, HR, or ECG recordings after any 
of the treatments or during the study. Thirteen 
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TABLE 3. Bronchial reactivity assessed by PD,, FEV, and DRS after study treatments, presented as 
median (range) 
Treatment PD,, FEV, @d DRS ((%I pmol ~ ‘) 
Placebo MDPI 
Salbutamol MDPI 
Salbutamol pMDI+ S 
250 (21-l 172) - 11.0 ( - 128.2 to - 2.5) 
1737 (13412300) - 2.0 ( - 25.9-0.36) 
622 (loll>2300) - 4.5 ( - 358-0.34) 
FIG. 1. The median PD,, FEV, @g) after Mch provoca- 
tion at screening visit, after placebo MDPI and after 
1OOpg of salbutamol either from Taifun= MDPI or from 
a pMD1 with a large volume spacer in 26 asthmatic 
patients. 
patients reported altogether 27 AEs during the study; all of 
them were mild and only ten were considered to be 
possibly or probably related to the study medication. Of all 
the AEs ten occurred on the screening visit, four after 
placebo MDPI, six after 100 pug salbutamol MDPI and 
seven after 1OOpg salbutamol from the pMDI+S. The 
respective numbers for the drug-related AEs were one, one, 
five and three. 
Discussion 
Mch provocation is a widely used method for assessing the 
acute effect of bronchodilating medication on bronchial 
hyperresponsiveness (11). Several well-documented modifi- 
cations of Mch provocations exist. The dosimeter method 
described by Nieminen et al. (8) was selected to be used in 
the present study, because it was the most familiar method 
for the study investigators since it was, with slight modifi- 
cations, already in clinical use in all of the present study 
centres. 
Asthma of the patients enrolled in this study was stable 
as demonstrated by the relatively small variability of 
the baseline FEV, between the study days. This enables 
accurate and repeatable measurement of bronchial respon- 
siveness, which is evidenced by the very similar median 
values in the measures of hyperresponsiveness on the 
screening visit and after treatment with placebo MDPI, 
which took place on average 5.7 days apart; PD,, FEV, 219 
and 25Opg and DRS - 12.1% and - 1 l.O%pmol~ ‘, at 
screening and after placebo MDPI, respectively. 
The DRS was chosen as a secondary efficacy parameter, 
because it was expected that after active treatment a 20% 
decline in FEV, could not be reached at least in some of 
the patients. Indeed, there was a significant amount of 
patients (12 after the Leiras MDPI and six after the 
pMDI+S) whose PD,, FEV, values could not be calcu- 
lated. The use of non-parametric statistics based on ranks 
somewhat reduced this problem, enabling fairly accurate 
analysis of the PD,, FEV, date. However, the complete 
and unhampered DRS data were additionally assessed as 
a confirmatory analysis. The DRS was first described by 
O’Connor et al. (9) for epidemiological purposes, and it 
was later found to be useful also in quantifying the 
efficacy of inhaled salbutamol in protecting against 
Mch-induced bronchoconstriction in healthy subjects (12). 
It can be calculated for all patients and in all conditions, 
so no data will be lost owing to limited change in 
pulmonary function. 
Analysed by either efficacy parameter, both active for- 
mulations were more effective than placebo Leiras MDPI, 
and lOOpug of salbutamol proved to be more effective 
when inhaled from the Leiras MDPI than from the 
pMDI+S in protecting against Mch-induced broncho- 
constriction. It is recognized that the clinical efficacy of an 
inhaled drug intended for treatment of asthma is related 
to the amount of drug deposited in the lungs (4). On this 
basis, it could be assumed that the airway deposition of 
salbutamol inhaled from Leiras MDPI is better than that 
when inhaled from a pMD1 connected to a VolumaticK‘ 
spacer. There are relatively few studies available assessing 
the lung deposition of salbutamol inhaled from a pMD1 
with a Volumatic “ spacer and, owing to differences in 
methods, subjects, design and the overall conditions of the 
studies, no direct comparisons can be made between 
different deposition studies. In healthy volunteers, after a 
salbutamol dose of 200 pug lung depositions from 2 1% (13) 
to 28% (14) have been reported. In asthmatic patients, 
19% of a metered dose of 200,~g was deposited in the 
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TABLE 4. The median (range) and 90% CI of the observed differences in PD,, FEV, values @g) 
between treatments 
Comparison Difference (range) 90% CI 
Salbumatol MDPI vs. placebo MDPI 1234 (39-2374) 851-1961 
Salbutamol MDPI vs. salbutamol pMDI+S 328 (- 1223-2345) 23-1017 
Salbutamol pMDI+S vs. placebo MDPI 314 (- 1652343) 123-759 
lungs (13). With Leiras MDPI the lung deposition after a 
dose of 2OOpg of salbutamol was 24% of the metered 
dose in healthy volunteers (5). However, the device has 
been improved since then in order to reduce the amount 
of drug retained in the mouthpiece, thus increasing the 
amount of the delivered dose and, consequently, the 
absolute dose of drug deposited in the lungs. Another 
thing that might have reduced the bronchoprotective effi- 
cacy of the pMDI+S is the bronchoconstrictive effect of 
CFC propellants seen in some asthmatic patients 
(2,15,16). Although a weak correlation between hyper- 
responsiveness and CFC sensitivity has been reported 
(17) it is unlikely that this would have affected the results 
of this study in general. Although the precise frequency of 
this phenomenon among asthmatics is not known, some 
large studies (15,16) indicate that only 14% of asthmatics 
suffer from it. In addition, the possible undesirable CFC 
effects are ‘naturally’ connected with the CFC-containing 
pMDIs, which is one of the reasons why alternative 
devices are under development. 
Because placebo pMDIs could not be obtained, this 
study was only partly blinded, and the pMDI+S served as 
an open control. Optimally, the study would have been 
double blinded by using a double-dummy technique. This 
lack of blindness in comparing the two devices with each 
other slightly reduces the value of this study since this 
allows, at least theoretically, some bias to occur in the 
measurements. However, the differences in the PD,, FEV, 
and DRS values between the treatments were so clear that 
this fault in the study design had probably no major effect 
on the results. 
The examination of the safety parameters or AEs did not 
reveal any differences between any of the treatments. All of 
the AEs were considered as mild or moderate and were 
regarded as harmless to the patient, and most of them were 
considered unrelated to the study medication. 
Taken together, a dose 100 pug of salbutamol inhaled 
from the Leiras MDPI offers clearly better protection 
against Mch-induced bronchoconstriction in asthmatic 
patients than does the same dose of salbutamol inhaled 
from a conventional pMD1 attached to a spacer. 
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